Dr. Reddy's Laboratories Limited (RDDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.91 Billion ≈ $12.75 Billion USD) by net assets (€375.76 Billion ≈ $439.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Dr. Reddy's Laboratories Limited's balance sheet to measure how much of total assets are equity-financed.
Dr. Reddy's Laboratories Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Dr. Reddy's Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RDDA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Dr. Reddy's Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy's Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuhan Jingce Electronic Technology Co Ltd
SHE:300567
|
-0.001x |
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
0.029x |
|
ICON PLC
NASDAQ:ICLR
|
0.044x |
|
MARKS SPENCER ADR LS-25
F:MA6A
|
N/A |
|
Bank of Ayudhya PCL
BK:BAY
|
0.017x |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
0.063x |
|
YTL Power International Bhd
KLSE:6742
|
0.069x |
|
Laurus Labs Limited
NSE:LAURUSLABS
|
0.222x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy's Laboratories Limited from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Dr. Reddy's Laboratories Limited market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €337.17 Billion ≈ $394.18 Billion |
€46.43 Billion ≈ $54.28 Billion |
0.138x | -14.97% |
| 2024-03-31 | €280.55 Billion ≈ $327.99 Billion |
€45.43 Billion ≈ $53.12 Billion |
0.162x | -35.95% |
| 2023-03-31 | €232.86 Billion ≈ $272.24 Billion |
€58.88 Billion ≈ $68.83 Billion |
0.253x | +71.38% |
| 2022-03-31 | €190.53 Billion ≈ $222.75 Billion |
€28.11 Billion ≈ $32.86 Billion |
0.148x | -27.70% |
| 2021-03-31 | €174.98 Billion ≈ $204.57 Billion |
€35.70 Billion ≈ $41.74 Billion |
0.204x | +5.97% |
| 2020-03-31 | €154.99 Billion ≈ $181.20 Billion |
€29.84 Billion ≈ $34.89 Billion |
0.193x | -5.96% |
| 2019-03-31 | €140.20 Billion ≈ $163.91 Billion |
€28.70 Billion ≈ $33.56 Billion |
0.205x | +43.61% |
| 2018-03-31 | €126.46 Billion ≈ $147.85 Billion |
€18.03 Billion ≈ $21.08 Billion |
0.143x | -17.80% |
| 2017-03-31 | €124.04 Billion ≈ $145.02 Billion |
€21.51 Billion ≈ $25.15 Billion |
0.173x | -- |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more